Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca’s Brilique receives new recommendation from NICE

AstraZeneca’s Brilique receives new recommendation from NICE

7th November 2016

AstraZeneca's anti-clotting agent Brilique has been recommended in a new indication in fresh guidance from the National Institute for Health and Care Excellence (NICE).

The UK regulator has endorsed the drug as a long-term treatment for patients who have had a heart attack and are at high risk of a further cardiovascular event, with the guidance recommending its use in a lower dosage than previously available.

Currently, Brilique can be used at a 90 mg dose with aspirin for 12 months after a heart attack, but the new NICE guidance means it can now be taken twice daily with aspirin at a 60 mg dose for a maximum of three years.

This recommendation was supported by clinical data from the PEGASUS study showing that Brilique was significantly more effective at reducing the risk of a second heart attack or stroke when used at a lower dose over a longer period of time.

Lisa Anon, AstraZeneca's president in the UK and Ireland, said: "With more people than ever surviving heart attacks, it is critical to recognise the need to provide ongoing management of the underlying condition in the immediate years following an attack for the prevention of further events."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801827957-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.